1301 related articles for article (PubMed ID: 26833159)
1. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
2. β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA.
Tran N; Rybak MJ
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29555635
[TBL] [Abstract][Full Text] [Related]
3. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208
[TBL] [Abstract][Full Text] [Related]
4. Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights.
Kebriaei R; Rice SA; Singh NB; Stamper KC; Nguyen L; Sheikh Z; Rybak MJ
J Antimicrob Chemother; 2020 Oct; 75(10):2894-2901. PubMed ID: 32591820
[TBL] [Abstract][Full Text] [Related]
5. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
Mirza HC; Sancak B; Gür D
Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
[TBL] [Abstract][Full Text] [Related]
6. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
7. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
9. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
Vidaillac C; Parra-Ruiz J; Rybak MJ
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
[TBL] [Abstract][Full Text] [Related]
10. Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.
Barber KE; Werth BJ; Ireland CE; Stone NE; Nonejuie P; Sakoulas G; Pogliano J; Rybak MJ
J Antimicrob Chemother; 2014 Nov; 69(11):3006-10. PubMed ID: 24990867
[TBL] [Abstract][Full Text] [Related]
11. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT
Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Biedenbach DJ; Arhin FF; Moeck G; Lynch TF; Sahm DF
Int J Antimicrob Agents; 2015 Dec; 46(6):674-81. PubMed ID: 26541881
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
Barber KE; Smith JR; Raut A; Rybak MJ
J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of oritavancin and comparators against meticillin-resistant Staphylococcus aureus (MRSA) isolates harbouring the novel mecC gene.
Arhin FF; Sarmiento I; Moeck G
Int J Antimicrob Agents; 2014 Jul; 44(1):65-8. PubMed ID: 24906505
[TBL] [Abstract][Full Text] [Related]
17. [In vitro activity of daptomycin against VRE and MRSA strains].
Aktaş G; Derbentli S
Mikrobiyol Bul; 2014 Jan; 48(1):123-8. PubMed ID: 24506722
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G
Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F
Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275
[TBL] [Abstract][Full Text] [Related]
20. Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
Lin G; Pankuch G; Appelbaum PC; Kosowska-Shick K
Antimicrob Agents Chemother; 2014 Oct; 58(10):6251-4. PubMed ID: 25022588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
